Q-omics provides the consensus-scored ELMOD3 profile across patient tissues and cancer cell-line models. ELMOD3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ELMOD3 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ELMOD3 RNA expression shows 20,238 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ELMOD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELMOD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELMOD3 survival associations across molecular data types. ELMOD3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELMOD3 RNA expression–survival associations across cancer types. High ELMOD3 expression shows unfavorable associations in KIRC, COAD, ACC and LGG, but favorable associations in PAAD and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ELMOD3 RNA expression.
This table summarizes ELMOD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ELMOD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELMOD3 shows lower tumor expression in THCA, BRCA and KICH and higher tumor expression in HNSC, LIHC and BLCA. The HNSC box plot shows higher ELMOD3 RNA expression in tumor versus normal tissue (log2 FC = +0.601, t-test p < 0.001).
This table shows molecular features associated with ELMOD3 in patient tissues and cancer cell lines. In patient samples, ELMOD3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ELMOD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
